D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 59 Citations 10,062 317 World Ranking 2478 National Ranking 16

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Internal medicine

His main research concerns Leukemia, Immunology, Cancer research, Myeloid and Myeloid leukemia. His study in Leukemia is interdisciplinary in nature, drawing from both Apoptosis, Cytopenia and T cell. His Immunology study frequently links to other fields, such as Internal medicine.

His Cancer research research includes themes of Haematopoiesis and Signal transduction. His studies in Myeloid integrate themes in fields like Molecular biology, Disease, Cell growth and Chromosomal translocation. His Myeloid leukemia research is multidisciplinary, relying on both Fms-Like Tyrosine Kinase 3, Regulation of gene expression, Gene, Gene isoform and Cell biology.

His most cited work include:

  • Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells (623 citations)
  • Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells (623 citations)
  • SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells (126 citations)

What are the main themes of his work throughout his whole career to date?

Immunology, Cancer research, Leukemia, Myeloid leukemia and Internal medicine are his primary areas of study. His research in Immunology intersects with topics in Stem cell and Transplantation. His Cancer research study incorporates themes from Apoptosis, Protein kinase B, Signal transduction and Gene expression.

His work deals with themes such as Myeloid, Molecular biology, Haematopoiesis and Cytokine secretion, which intersect with Leukemia. His Myeloid leukemia research integrates issues from Cell, PI3K/AKT/mTOR pathway, Retinoic acid and Pharmacology. His Internal medicine research includes elements of Gastroenterology, Endocrinology and Oncology.

He most often published in these fields:

  • Immunology (65.73%)
  • Cancer research (49.89%)
  • Leukemia (47.07%)

What were the highlights of his more recent work (between 2016-2021)?

  • Myeloid leukemia (50.33%)
  • Cancer research (49.89%)
  • Immunology (65.73%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Myeloid leukemia, Cancer research, Immunology, Stem cell and Internal medicine. The study incorporates disciplines such as Cytokine, Myeloid, Bone marrow, PI3K/AKT/mTOR pathway and Retinoic acid in addition to Myeloid leukemia. His biological study spans a wide range of topics, including Protein kinase B, Tyrosine kinase, Downregulation and upregulation, Leukemia and Kinase.

Øystein Bruserud has included themes like Lonidamine, Signal transduction and Disease in his Leukemia study. His Immunology study frequently involves adjacent topics like Haematopoiesis. His Hematology study in the realm of Internal medicine interacts with subjects such as In patient.

Between 2016 and 2021, his most popular works were:

  • Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms (37 citations)
  • Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms (37 citations)
  • Interleukin-6 in allogeneic stem cell transplantation: Its possible importance for immunoregulation and as a therapeutic target (28 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Internal medicine

The scientist’s investigation covers issues in Myeloid leukemia, Cancer research, Immunology, Cytokine and PI3K/AKT/mTOR pathway. The concepts of his Myeloid leukemia study are interwoven with issues in Myeloid, Tyrosine kinase, Proteome and Bone marrow. The Cancer research study combines topics in areas such as Cell, Cellular differentiation, Receptor, Syk and Leukemia.

Øystein Bruserud interconnects Chronic fatigue and Stem cell in the investigation of issues within Immunology. His Stem cell study incorporates themes from Transplantation and Minimal residual disease. His work carried out in the field of Cytokine brings together such families of science as Tumor necrosis factor alpha, Sepsis, Chemokine, Intracellular and Allergy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells

Jonathan M Irish;Randi Hovland;Peter O Krutzik;Omar D Perez.
Cell (2004)

815 Citations

SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells

Ling Li;Tereza Osdal;Yinwei Ho;Sookhee Chun.
Cell Stem Cell (2014)

194 Citations

Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells

O. Bruserud;C. Stapnes;E. Ersvær;B. T. Gjertsen.
Current Pharmaceutical Biotechnology (2007)

170 Citations

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life

Jan Samuelsson;Hans Hasselbalch;Oystein Bruserud;Snezana Temerinac.
Cancer (2006)

145 Citations

Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities

Øystein Bruserud;Randi Hovland;Line Wergeland;Tien-Sheng Huang.
Haematologica (2003)

140 Citations

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.

Camilla Stapnes;Anne P. Døskeland;Kimberley Hatfield;Elisabeth Ersvær.
British Journal of Haematology (2007)

138 Citations

Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells.

Jenny Foss Abrahamsen;Anne M. Bakken;Øystein Bruserud.
Transfusion (2002)

135 Citations

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.

Øystein Bruserud;Anita Ryningen;Astrid Marta Olsnes;Laila Stordrange.
Haematologica (2007)

133 Citations

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications

Håkon Reikvam;Kimberley Joanne Hatfield;Astrid Olsnes Kittang;Astrid Olsnes Kittang;Randi Hovland.
BioMed Research International (2011)

130 Citations

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents

Hanne Kristin Fredly;Bjørn Tore Gjertsen;Bjørn Tore Gjertsen;Øystein Bruserud;Øystein Bruserud.
Clinical Epigenetics (2013)

116 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Øystein Bruserud

Bjørn Tore Gjertsen

Bjørn Tore Gjertsen

Haukeland University Hospital

Publications: 84

Garry P. Nolan

Garry P. Nolan

Stanford University

Publications: 71

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 19

Lars A. Akslen

Lars A. Akslen

University of Bergen

Publications: 16

Stein Ove Døskeland

Stein Ove Døskeland

University of Bergen

Publications: 16

Richard Moriggl

Richard Moriggl

University of Veterinary Medicine Vienna

Publications: 12

Ruben A. Mesa

Ruben A. Mesa

The University of Texas Health Science Center at San Antonio

Publications: 12

Steven M. Kornblau

Steven M. Kornblau

The University of Texas MD Anderson Cancer Center

Publications: 11

Wolfgang E. Berdel

Wolfgang E. Berdel

University of Münster

Publications: 11

Mark D. Minden

Mark D. Minden

Princess Margaret Cancer Centre

Publications: 11

Carsten Müller-Tidow

Carsten Müller-Tidow

University Hospital Heidelberg

Publications: 11

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 11

Satu Mustjoki

Satu Mustjoki

University of Helsinki

Publications: 11

Srdan Verstovsek

Srdan Verstovsek

The University of Texas MD Anderson Cancer Center

Publications: 11

Marina Konopleva

Marina Konopleva

The University of Texas MD Anderson Cancer Center

Publications: 11

Xiao-Jun Huang

Xiao-Jun Huang

Peking University

Publications: 10

Trending Scientists

Martin T. Zanni

Martin T. Zanni

University of Wisconsin–Madison

Michito Yoshizawa

Michito Yoshizawa

Tokyo Institute of Technology

Qing-Hua Xu

Qing-Hua Xu

National University of Singapore

Peter Model

Peter Model

Rockefeller University

Taizo Hogetsu

Taizo Hogetsu

University of Tokyo

Matthias Wilm

Matthias Wilm

University College Dublin

Ranjan Swarup

Ranjan Swarup

University of Nottingham

Richard Calderone

Richard Calderone

Georgetown University Medical Center

Martin Melles

Martin Melles

University of Cologne

Giles F.S. Wiggs

Giles F.S. Wiggs

University of Oxford

Frédéric Herman

Frédéric Herman

University of Lausanne

Douglas W. Oldenburg

Douglas W. Oldenburg

University of British Columbia

Arthur M. Winer

Arthur M. Winer

University of California, Los Angeles

Jon S. Friedland

Jon S. Friedland

St George's, University of London

Stephen E. G. Lea

Stephen E. G. Lea

University of Exeter

Colin R. Dunstan

Colin R. Dunstan

University of Sydney

Something went wrong. Please try again later.